Regenerative Medicine

The FDA granted fast track and regenerative medicine advanced therapy designations to CB-010, a chimeric antigen receptor T-cell therapy, for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.

Tissue regeneration has been achieved in certain parts of the body, but not the heart. That could change if a novel therapeutic derived from messenger RNA succeeds.

Clinicians need to be aware of the contents of the June 3 memo from the FDA regarding use of human cell and tissue products and must realize that the guidance issued Nov. 15, 2017, has not changed, according to a regulatory consultant.

From a clinical perspective, increased options for cataract surgeons and transformative retina research embodied 2020, according to panelists at the virtual Ophthalmology Innovation Summit Year in Review meeting.

While poor regulation and unsafe products are prevalent, novel pain management strategies such as stem cells and electrical stimulation nevertheless provide hope for patients, according to a presenter at the 2020 Congress of Clinical Rheumatology-East.

At the end of 2017, with the demand for the use of biologics in orthopedics outstripping the science as well as the safety and efficacy information available, leaders of the Arthroscopy Association of North American, the American Orthopaedic Society for Sports Medicine and the International Cartilage Regeneration and Joint Preservation Society formed the Biologic Association to provide high-level evidence to physicians and patients and to advance this treatment.

The FDA granted regenerative medicine advanced therapy designation to tisagenlecleucel — a chimeric antigen receptor T-cell therapy — for patients with relapsed or refractory follicular lymphoma, according to a press release issued by the manufacturer.

The Arthroscopy Association of North America, the American Orthopaedic Society for Sports Medicine, the International Cartilage Repair Society and the Orthoregeneration Network Foundation have collaborated to form the Biologics Alliance, which will discuss all issues on musculoskeletal biologics and regenerative medicine.

Cedars-Sinai researchers have received a $10.5 million grant from the California Institute for Regenerative Medicine to launch a clinical trial evaluating stem cell technology for the treatment of retinitis pigmentosa, according to a press release.

NEWPORT BEACH, Calif. — The unmet needs in the medical aesthetics market currently reside in hair growth, skin tightening and texture, and acne device-based technologies, according to researchers here at a session on medical innovation in aesthetics.